[Influence of splenectomy on drug therapy for acute liver failure induced by D-galactosamine and lipopolysaccharide in rats].
We studied protective effects of dibutyryl cyclic AMP (DBcAMP 15 mg/kg i.p.) and OK-432 (5 KE/body), and the role of the spleen on D-galactosamine (D-Gal 500 mg/kg i.p.) and lipopolysaccharide (endotoxin: Et 0.5 mg/kg i.p.) induced acute liver failure. The survival rates were 10% in the control group (D-Gal+Et), 53% in the group I A (DBcAMP was administered at 1 hour before D-Gal administration), 79% in the group I B (Splenectomy was performed at 24 hours before D-Gal administration on the group I A), 87% in the group II A (OK-432 was administered at 24 hours before D-Gal administration), and 64% in the group II B (Splenectomy was performed at 24 hours before D-Gal administration on the group II A). GOT activities and TNF activities were significantly improved in the treatment groups, and in the group I B and group II A, they were more improved than in the group I A and group II B. In conclusion, spleen had the positive effect for OK-432 treatment, and also had the negative effect for DBcAMP treatment on acute liver failure induced by D-Gal and Et.
Kudo
K
K
Second Department of Surgery, Asahikawa Medical College.
Kakisaka
A
A
Kasai
S
S
Mito
M
M
D000818:Animals; D003994:Bucladesine / Q000627:therapeutic use; D005688:Galactosamine; D008070:Lipopolysaccharides; D017114:Liver Failure, Acute / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D010844:Picibanil / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000502:physiology*; D013156:Splenectomy
D008070:Lipopolysaccharides; D010844:Picibanil; D003994:Bucladesine; D005688:Galactosamine